Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Cash from Investing Activities (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Cash from Investing Activities data on record, last reported at $29.1 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 45.43% year-over-year to $29.1 million; the TTM value through Dec 2025 reached $116.8 million, up 520.2%, while the annual FY2025 figure was $116.8 million, 520.2% up from the prior year.
  • Cash from Investing Activities reached $29.1 million in Q4 2025 per TRDA's latest filing, down from $49.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $53.4 million in Q4 2024 and bottomed at -$181.5 million in Q1 2022.
  • Average Cash from Investing Activities over 4 years is -$12.4 million, with a median of $11.8 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: plummeted 2119.08% in 2024, then soared 238.61% in 2025.
  • A 4-year view of Cash from Investing Activities shows it stood at $18.8 million in 2022, then rose by 1.34% to $19.0 million in 2023, then surged by 180.23% to $53.4 million in 2024, then plummeted by 45.43% to $29.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were $29.1 million in Q4 2025, $49.1 million in Q3 2025, and $33.8 million in Q2 2025.